U.S. Markets closed
  • S&P Futures

    4,529.75
    +21.25 (+0.47%)
     
  • Dow Futures

    34,166.00
    +164.00 (+0.48%)
     
  • Nasdaq Futures

    15,951.75
    +82.00 (+0.52%)
     
  • Russell 2000 Futures

    2,155.50
    +9.20 (+0.43%)
     
  • Crude Oil

    65.83
    +0.26 (+0.40%)
     
  • Gold

    1,782.10
    -2.20 (-0.12%)
     
  • Silver

    22.41
    +0.07 (+0.30%)
     
  • EUR/USD

    1.1339
    +0.0017 (+0.1474%)
     
  • 10-Yr Bond

    1.4340
    -0.0090 (-0.62%)
     
  • Vix

    31.12
    +3.93 (+14.45%)
     
  • GBP/USD

    1.3305
    +0.0028 (+0.2076%)
     
  • USD/JPY

    113.0340
    +0.2540 (+0.2252%)
     
  • BTC-USD

    56,974.29
    +113.73 (+0.20%)
     
  • CMC Crypto 200

    1,449.11
    -19.97 (-1.36%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,748.41
    -187.21 (-0.67%)
     

Can SurModics (SRDX) Run Higher on Rising Earnings Estimates?

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SurModics (SRDX) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.

The upward trend in estimate revisions for this drug delivery technology company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For SurModics, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate Revisions

The earnings estimate of $0.10 per share for the current quarter represents a change of -33.33% from the number reported a year ago.

Over the last 30 days, the Zacks Consensus Estimate for SurModics has increased 350% because one estimate has moved higher compared to no negative revisions.

Current-Year Estimate Revisions

The company is expected to earn $0.20 per share for the full year, which represents a change of -72.22% from the prior-year number.

The revisions trend for the current year also appears quite promising for SurModics, with one estimate moving higher over the past month compared to no negative revisions. The consensus estimate has also received a boost over this time frame, increasing 300%.

Favorable Zacks Rank

Thanks to promising estimate revisions, SurModics currently carries a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom Line

SurModics shares have added 11.2% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Surmodics, Inc. (SRDX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research